there's a difference between previous news of TauRx and recent news. Previous news before 2024 is without submission to regulatory bodies for marketing authorization. Recent news in 2nd half of 2024 is confirmed submission to UK MHRA for marketing authorization for UK market. That is a big difference in terms of progress. What's next - the decision from UK MHRA on whether to approve HMTM by TauRx for marketing authorization or reject it / conditional MA. Thereafter, NICE will review and make a decision on whether to approve HMTM for use in NHS; the public/gomen hospital if you will. Marketing authorization approval by UK MHRA means HMTM can be manufactured for sale in the UK.

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision not to recommend the Alzheimer’s treatments Kisunla (donanemab) and Leqembi (lecanemab) for use on the National Health Service (NHS) in England.
This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative coverage decision for Eli Lilly’s Kisunla came in October 2024.
Following a request for additional evidence, NICE’s independent appraisal committee reviewed new data but maintained its stance that the medicines are not cost-effective. NICE stated that neither treatment provides sufficient benefit to justify the significant cost of provision and administration within the NHS.

The committee concluded that even under a managed access arrangement – where drugs are provided at a discounted price for a fixed period while additional evidence is collected – was not acceptable. “The cost-effectiveness estimates for donanemab and lecanemab remain substantially higher than we can consider an acceptable use of taxpayers’ money and NHS resources,” said NICE in the 6 March announcement.

The draft guidance has now been opened for public consultation, which will close on 27 March 2025, after which NICE will convene a third appraisal meeting to consider responses before issuing final recommendations. Kisunla and Leqembi are both monoclonal antibodies designed to slow early cognitive decline in Alzheimer’s patients by targeting amyloid beta plaques in the brain. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved both treatments in 2024, becoming the first regulatory agency to do so.

Yes, thats the possible second news in Apr. NICE has rejected the other two approved Alzheimer IV drugs for NHS use and if you can recall in previous posting, NICE is also working/assessing HMTM by TauRx - its paused for now pending UK MHRA decision.

GenM can manage the RWNYC license fees without Genting, Sky Liew. And they can enable the table games pretty fast since they have the casino facility in place and start generating income. The development project on the area will probably take at least 2 to 3 years to complete. The real challenge / question will be Thailand IR. Unlikely GenM can handle two projects at the same time financially. For me, I will wait for the RWNYC outcome by Dec to decide whether to continue holding Genting or exit. Not inclined to hold if (1) if both RWNYC and Steve Cohen's bids are successful (2) successful RWNYC full casino license AND Thailand's IR at the same time

Hopefully the new native CEO and COO of Las Vegas able to improve operations and GenM get New York casino license and better off sell Miami land and Empire then I believe Genting and GenM will reflect fair value.. Egypt operations indeed also not really give much future value especially so near Israel and Palestian..

Agreed. RWLV is one of the 3 main anchor for leisure hospitality segment. MY asset and SG asset. GenM's top US asset is RWNYC followed by Hudson Valley. Catskills is not making enough and inconsistent. Can't do much on Bahamas segment until next year due to the shareholder dispute.

IBs are now aligned to potential MAA decision in Apr too :) Genting Bhd's $10.5 million settlement with Nevada regulators on a compliance complaint could encourage gamblers to return to Resorts World Las Vegas, Maybank IB analyst Yin Shao Yang notes. The company retains its license, and the fine represents less than 5% of its 2025 expected earnings, he notes. A rebound in gambler traffic could lift RWLV average quarterly Ebitda to $37.5 million going forward, compared with about $1.5 million in 4Q 2024, he reckons. The Lim family and CEO increasing their stake recently also signals confidence in Genting's long-term value, he says. A potential Alzheimer's drug approval for its associate TauRx Pharmaceuticals in April or May remains a key upside catalyst, he adds. Maybank maintains a buy rating on Genting and keeps target price at MYR3.98. Shares are unchanged at MYR3.32. (yingxian.wong@wsj.com)

unlikely, Vin. The process typically involves the attorney general representing the Gaming Board and Gent (RWLV board/lawyer/counsel) to discuss the settlement discussions. Once settlements have been agreed upon by both parties, it goes to next step; stipulation for settlement and order. I didnt notice any violent objections from Genting for the proposed settlements.

You can open up the document link I sent on Friday. Its stated as Stipulation for Settlement and Order. Its showing pending bcos the next step is to have it approved by the Gaming Commission. And it has been scheduled for the commission approval on 27th Mar; page 2 agenda #5 :) https://gaming.nv.gov/uploadedFiles/gamingnvgov/content/about/agenda-disposition/March%202025%20NGC%20Agenda%20(1).pdf

You are welcome, Vin. The market sentiment is poor. KLCI is in correction territory and yet to enter technical bear though. Most of the sectors are already in bear market with tech sector being the worst due to overvaluations and DeepSeek adding salt to the AI wound. Gent was beaten irrationally starting back in Aug'24 due to the fear of license being revoked and temporary earnings disruptions from GenS. The former is considered done deal and looking forward to the super luxury all suite hotel and Oceanarium opening in Q3 for the latter.

LKT is indeed buying aggressively, Vin. Its end of Mar now and the USD strength has cooled down from the recent peak back in q4'24. There should not be surprises from forex. The US segment performance will be the deciding factor for Gent's performance. SG and MY performance should be decent due to festive season. News wise - possible MAA decision in Apr, openings in Q3 for GenS, and possible rate cut second half of the year.

I dont have the exact RWLV performance in January as Nevada Gaming Board did not publish individual casino performance. However, you can get a feel how the industry is doing by looking at the numbers from statewide and the strip area where RWLV is located. Page 1 %change for Jan'25 showing total gaming 12.5% increase yoy statewide while page 12 %change for Jan'25 showing total gaming 22.5% increase yoy for the strip area. Pretty good numbers if you will. https://gaming.nv.gov/uploadedFiles/gamingnvgov/content/about/gaming-revenue/2025Jan-gri.pdf

You are welcome, Vin. We have no controls over the market force. I guessed many are disappointed with the lack of positive headwinds in Malaysia stock market. S&P500 will be closely watched as it is not going to be easy to make a new high for 2025; coupled with tariffs and fiscal/monetary policies uncertainties. S&P500 has just rebounded from correction territory recently and giving a breather from sentiment perspective. I am still in the opinion that buying/selling for the short term will be difficult comparing to the last two years. One day sunny and the next day stormy if you will. Volatility will be high with violent ups and downs.

Index supported by EPF and local insti, Vin. Lets see how Genting performs in the quarter end rebalancing. Genting is still part of the MSCI emerging market index after all; visibility from the foreign funds. And LKT is still buying aggressively.